Navigation Links
Model-Based Drug Development 101, a new Xtalks webinar
Date:2/6/2013

Toronto, Canada (PRWEB) February 06, 2013

As the development of new drugs is becomes increasingly expensive and lengthy process, it’s clear that new approaches must be explored.

With model-based drug development (MBDD), mathematical models can be used early on to test extremely complex situations before deciding on a course of action. These models can identify the right dose, the right population, optimize clinical protocol, program, and portfolio designs, and compare candidates with existing drugs — ultimately providing better decisions and optimized returns.

Expert speakers will provide an overview of the basics of model based drug development and its practical applications — from electing the right dose and population to optimizing trial, program, and portfolio design.

Attendees will get a sense of how model- based drug development can help to:

  •     Improve communication across disciplines
  •     Utilize the many data domains to improve drug development
  •     Make better, quantitative, data-driven decisions

A live Q&A with the audience will follow the main presentation.

For more information about this event or to register, http://xtks.in/xto569-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/2/prweb10386010.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors
2. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
3. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
4. Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
5. ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents
6. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
7. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
8. Idenix Reports Advancement of HCV Development Pipeline
9. Almost perfect: A breakthrough in superlens development
10. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
11. New Software from SRI Speeds Development of Genome-Scale Models for Drug and Fuel Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2016)... ... 2016 , ... Doctors in Rome say micronutrients found in certain foods have ... Mesothelioma has just posted an article on the new research. Click here to ... Sciences and Translational Medicine evaluated more than 150 studies on polyphenols in cancer for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers ... a new way to treat the disease. Surviving Mesothelioma has just posted an article ... from several Korean institutions based their mesothelioma study on the fact the Manumycin A, ...
(Date:5/19/2016)... , May 19, 2016  AdvancedFlow Systems ... Inc. (AGI), based out of Maple ... Biogas Ltd. to its existing portfolio of contract ... agreement. AFS along with its sister companies Surround ... a vertically integrated industrial group that specializes in ...
(Date:5/19/2016)... May 19, 2016 ... (OTC PINK: RGBPP) announced today initiation of a ... cord blood based cancer immunotherapeutic product leveraging its ... Regen described a generation of cord blood derived ... gene silencing.  The product in development will be ...
Breaking Biology Technology:
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):